Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Works With Roche To Increase Diagnostic Services For Xalkori Launch In China’s Self-Pay Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite no reimbursement in sight, Pfizer still sees a huge potential for targeted lung cancer drug Xalkori in China. To quickly ramp up eligible patients, Pfizer is working with Roche to offer discounted diagnostic services to identify best responders.

You may also be interested in...



Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs

Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.

Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge

The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.

China-US Tensions Rise Sharply On Pelosi Visit, Will Biotech Get Burned?

Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel